search

All clinical trials

Results 460241-460250 of 470744

Expanded Access Study for Renal Transplant Patients With Envarsus XR ™

Renal Failure

Open label, multi-center, expanded access study for renal transplant patients with once daily Envarsus XR (Tacrolimus).

Approved for marketing13 enrollment criteria

An Expanded Access Study of Brigatinib for Patients With ALK-positive Advanced Non-Small Cell Lung...

Non-small Cell Lung CancerLung Cancer2 more

The purpose of this study is to provide brigatinib for those patients with locally advanced and/or metastatic patients with ALK+ NSCLC on an expanded access basis due to their inability to meet eligibility criteria for on-going recruiting trials, inability to participate in other clinical trials (e.g., poor performance status, lack of geographic proximity), or because other medical interventions are not considered appropriate or acceptable.

No longer available22 enrollment criteria

Expanded Access to VAL-083

Cancer

This is an expanded access program (EAP) for eligible participants. This program is designed to provide access to VAL-083 (dianhydrogalactitol) prior to approval by the local regulatory agency. Availability will depend on territory eligibility. Participating sites will be added as they apply for and are approved for the EAP. A medical doctor must decide whether the potential benefit outweighs the risk of receiving an investigational therapy based on the individual patient's medical history and program eligibility criteria.

Available3 enrollment criteria

Margetuximab Expanded Access Program

HER2-positive Breast CancerHER2-positive Carcinoma

The purpose of the Expanded Access program is to provide margetuximab to patients with pretreated HER2+ breast cancer for whom potential benefit justifies potential treatment risks.

Approved for marketing2 enrollment criteria

Expanded Access to ABT-414

Glioblastoma or Solid TumorsEpidermal Growth Factor Receptor (EGFR) Diagnosis

This is an expanded access program (EAP) for eligible participants. This program is designed to provide access to ABT-414 prior to approval by the local regulatory agency. Availability will depend on territory eligibility. Participating sites will be added as they apply for and are approved for the EAP. A medical doctor must decide whether the potential benefit outweighs the risk of receiving an investigational therapy based on the individual patient's medical history and program eligibility criteria.

No longer available4 enrollment criteria

An Expanded Access Program of Ipilimumab for Patients With Glioblastomas and Gliomas

GlioblastomaGlioma of Brain

IPILIMUMAB Extended Access Program for patients who received chemotherapy and / or radiation therapy before the protocol, before or after the operation.

No longer available43 enrollment criteria

AMG 714 Expanded Access Program

Celiac Disease

Expanded access requests for AMG 714 may be considered for adult patients with biopsy proven Refractory Celiac Disease Type II who have failed all available treatment options and do not have EATL. To request access, use Responsible Party contact information provided in this record.

Available2 enrollment criteria

An Expanded Access Program for AM0010 (Pegilodecakin)

MelanomaProstate Cancer7 more

This is an Expanded Access Program (EAP) available to patients who have advanced cancers, who have failed or progressed on standard of care systemic therapy and do not qualify for ongoing clinical trials.

No longer available5 enrollment criteria

Safety and Treatment Outcome Study of PROCHYMAL® (Remestemcel-L) Intravenous Infusion in Subjects...

Crohn's Disease

Protocol 620 provides PROCHYMAL(R) adult human mesenchymal cells to specifically chosen Crohn's disease patients at participating centers who typically have already demonstrated good response in another PROCHYMAL study, are not eligible for other PROCHYMAL studies, and in the view of the investigator, would not benefit significantly from other Crohn's therapies but would benefit from use of PROCHYMAL. The study is not placebo-controlled or randomized.

No longer available18 enrollment criteria

Emergency Use of OCR-002 in Acute Liver Failure (ALF)

Acute Liver Failure

This study provides emergency use of the unapproved study medication in ALF patients with acute liver failure who are not responding to standard of care.

No longer available3 enrollment criteria
1...460244602546026...47075

Need Help? Contact our team!


We'll reach out to this number within 24 hrs